Table 1 Baseline sociodemographic and clinical characteristics of pediatric patients with COVID-19 and rheumatic diseases
Variable | RMD COVID-19 patients n = 77 | RMD COVID-19 symptomatic patients n = 47 | RMD COVID-19 asymptomatic patients n = 30 | p value* |
|---|---|---|---|---|
Women, n (%) | 55 (71.43) | 31 (65.95) | 24 (80) | 0.20 |
Age, mean (SD), years | 11.88 (4.04) | 12.04 (4.22) | 11.63 (3.81) | 0.53 |
Clinical remission, n (%) | 52 (67.53) | 28 (59.57) | 24 (80) | 0.37 |
Comorbidities | 8 (10.39) | 8 (17.02) | 0 | 0.02 |
Diagnosis, n (%) | 0.53 | |||
Chronic inflammatory arthritis | ||||
Oligoarticular JIA | 21 (27.27) | 9 (19.14) | 12 (40) | |
Oligoarticular JIA with associated uveitis | 9 (11.69) | 5 (10.63) | 4 (13.33) | |
Polyarticular JIA | 12 (15.58) | 8 (17.02) | 4 (13.33) | |
Enthesitis-related arthritis | 4 (5.19) | 3 (6.38) | 1 (3.33) | |
Idiopathic uveitis | 2 (2.60) | 2 (4.25) | 0 | |
Multisystemic autoimmune disorders | ||||
Systemic lupus erythematosus | 8 (10.38) | 6 (12.76) | 2 (6.66) | |
Scleroderma | 1 (1.30) | 1 (2.12) | 0 | |
Idiopathic inflammatory myopathy | 3 (3.90) | 2 (4.25) | 1 (3.33) | |
Pediatric vasculitis | 2 (2.60) | 1 (2.12) | 1 (3.33) | |
Autoinflammatory diseases | ||||
Systemic JIA | 5 (6.49) | 4 (8.51) | 1 (3.33) | |
Chronic recurrent multifocal osteomyelitis | 3 (3.90) | 2 (4.25) | 1 (3.33) | |
PFAPA syndrome | 2 (2.60) | 2 (4.25) | 0 | |
Monogenic autoinflammatory syndrome | 5 (6.49) | 2 (4.25) | 3 (10) | |
Rheumatic disease treatment, n (%) | ||||
NSAIDs, n (%) | 3 (3.90) | 2 (4.25) | 1 (3.33) | 0.99 |
Glucocorticoids, n (%) | 9 (11.69) | 7 (14.89) | 2 (6.66) | 0.46 |
csDMARDsa, n (%) | 35 (45.45) | 22 (46.80) | 13 (43.33) | 0.81 |
Ts/bDMARDsb, n (%) | 40 (51.95) | 24 (51.05) | 16 (53.33) | 0.99 |